MFDCH016
MFDCH016 is a potent HDAC1/6 (IC50 = 38/59 nM) and CDK4/6 (IC50 = 680/720 nM) inhibitor. MFDCH016 induces apoptosis and cell cycle arrest in G2/M and G0/G1 phases in MCF-7 cells. MFDCH016 can modulate the HDAC-p21-CDK signaling pathway, increasing the levels of acetylated H3 and p21. MFDCH016 can be used for the study of breast cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Formel: C27H34N8O4
- Molecular Weight:534.61
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle Histamine Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
In Vitro
MFDCH016 (1 μM, 10 μM, 72 h) shows a proliferation inhibition rate of 55% and 86% against MCF-7 cells at concentrations of 1 μM and 10 μM, respectively[1].
MFDCH016 (1 μM, 10 μM) dose-dependently inhibits the cell activity of a range of cancer cell lines, including MCF-7, T47D, A549, NCI-H460, NCI-H1299, FaDu, UDSCC-2, MC38, and CT26[1].
MFDCH016 (0.001-100 μM) has a good inhibitory effect on MCF-7 breast cancer cells (GI50 = 2.476 μM) [1].
MFDCH016 (12-72 h) effectively inhibits tumor cell proliferation in MCF-7 cells, characterized by G0/G1 phase cell cycle arrest, a significant reduction in S-phase and G2/M populations, and culminating in apoptosis, alongside significantly upregulating acetyl-H3 and p21 protein levels and downregulating cyclin D1 expression, effects which increased over time and peaked at 72 hours[1].
MFDCH016 (10 μM) shows low cardiotoxicity to all hERG channels in the hERG-HEK Stable cell line, with an average inhibition rate of 22.8% at a concentration of 10 μM[1].
MFDCH016 exhibits negligible activity against other CDKs (IC50 > 5000 nM for most isoforms, and >10,000 nM for CDK1, CDK2, CDK7, and CDK10), yielding selectivity folds exceeding 700-fold over non-target CDKs[1].
MFDCH016 demonstrates moderate inhibition of CYP1A2 (20.7 %), CYP2C9 (29.2 %), and CYP2C19 (26.5 %), while exhibiting lesser inhibition of CYP2D6 (14.8 %)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MCF-7 human breast cancer cell line
-
Concentration:1 μM, 10 μM
-
Incubation Time:72 h
-
Result:Showed a proliferation inhibition rate of 55% and 86% against MCF-7 cells at concentrations of 1 μM and 10 μM, respectively.
Parmacokinetics
| Species | Dose | Route | T1/2 | AUC0-t | AUC0-∞ | CL | Vss | Cmax | Tmax |
|---|---|---|---|---|---|---|---|---|---|
| Mice | 2.5 mg/kg | i.v. | 0.45 h | 306 ng·h/mL | 313 ng·h/mL | 8.2 L/h/kg | 2.8 L/kg | / | / |
| Mice | 30 mg/kg | p.o. | 2.7 h | 378 ng·h/mL | 407 ng·h/mL | / | / | 411 ng/mL | 0.21 h |
| Mice | 5 mg/kg | i.p. | 0.49 h | 84 ng·h/mL | 89 ng·h/mL | / | / | 147 ng/mL | 0.13 h |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MCF-7 xenograft model using BALB/c female mice (n = 4/6 per group)[1].
-
Dosage:40 mg/kg
-
Administration:I.p., once daily for 14 days
-
Result:Exhibited a strong antitumor effect, with a low average tumor weight.
Body weight remained stable, with no evidence of toxicity or weight loss.
Chemical Information
-
Molecular Weight 534.61
-
Formel C27H34N8O4
-
SMILES
CC(C1=C(C2=CN=C(N=C2N(C1=O)C3CCCC3)NCCC4CCN(CC4)C5=NC=C(C=N5)C(NO)=O)C)=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)